Geisinger Medical Laboratories Test Catalog
MYGENVAR MYELOPROLIFERATIVE PANEL, NEXT GENERATION SEQUENCING |
|||||||||||||||||||||||||||||||||||||||||||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3508 Geisinger Epic ID: 66456 | ||||||||||||||||||||||||||||||||||||||||||
SPECIMEN COLLECTION |
|||||||||||||||||||||||||||||||||||||||||||
Specimen type: |
Whole blood | ||||||||||||||||||||||||||||||||||||||||||
Preferred collection container: |
|||||||||||||||||||||||||||||||||||||||||||
Alternate Collection Container: |
3 mL lavender-top (K2 EDTA) tube
|
||||||||||||||||||||||||||||||||||||||||||
Specimen required: |
Three (3) 6 mL pink-top K2 EDTA tubes (minimum 4 mL each) whole blood OR six (6) 3 mL lavender-top K2 EDTA tubes. | ||||||||||||||||||||||||||||||||||||||||||
Special notes: |
Collect three (3) 6 mL pink-top K2 EDTA tubes OR six (6) 3 mL lavender-top K2 EDTA tubes | ||||||||||||||||||||||||||||||||||||||||||
SPECIMEN PROCESSING |
|||||||||||||||||||||||||||||||||||||||||||
Specimen processing instructions: |
Mix well immediately. Send/deliver all collection tubes to GMC Molecular Diagnostic Lab. Store at 2-8°C. Do not centrifuge. | ||||||||||||||||||||||||||||||||||||||||||
Transport temperature: |
Refrigerated, 2-8°C. Send to GMC Molecular Diagnostic Lab. | ||||||||||||||||||||||||||||||||||||||||||
Specimen stability: |
Refrigerated, 2-8°C: 3 days. Specimen must be extracted within 3 days. | ||||||||||||||||||||||||||||||||||||||||||
Rejection criteria: |
Wrong collection tube. Improper storage or transport temperature. Stability limits exceeded. Shared or comingled specimens. | ||||||||||||||||||||||||||||||||||||||||||
TEST DETAILS |
|||||||||||||||||||||||||||||||||||||||||||
Reference interval: |
Negative (no mutations detected). | ||||||||||||||||||||||||||||||||||||||||||
Additional information: |
For molecular testing, original tube required. | ||||||||||||||||||||||||||||||||||||||||||
CPT code(s): |
81450 | ||||||||||||||||||||||||||||||||||||||||||
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | |||||||||||||||||||||||||||||||||||||||||||
Test includes: |
BCR-ABL1, JAK2, CALR, MPL, and CSF3R mutations detected by Next Generation Sequencing.
RNA Based BCR-ABL1 Analysis: Provides qualitative information on the absence or presence of BCR-ABL1 fusion transcripts including the most common BCR-ABL1 transcripts e1a2 (p190), e13a2 (p210), and e14a2 (p210) at = 0.1% frequency in wild-type background. In addition to the e1a2, e13a2, and e14a2 transcript variants, this assay is predicted to detect rare alternative BCR-ABL1 break/fusion events including e19a2 (p230). False negative results are possible if mutant cells are below the analytical sensitivity of the method or alternative break/fusion events that result in unusual BCR-ABL1 transcript types.
|
||||||||||||||||||||||||||||||||||||||||||
Methodology: |
DNA Extraction Next Generation Sequencing RNA extraction |
||||||||||||||||||||||||||||||||||||||||||
Synonyms: |
BCRABL, BCR-ABL1, p210, p190, JAK2, JAK-2, Janus Tyrosine Kinase 2, CALR, Calreticulin, MPL, Thrombopoietin Receptor, CSF3R, Colony Stimulating Factor 3 Receptor, Thrombocytosis, MPD, Myeloproliferative Disorder, MPDSP
|
||||||||||||||||||||||||||||||||||||||||||
Clinical significance: |
This test detects mutations associated with myeloproliferative disorders that are informative in the diagnosis and management of disease. | ||||||||||||||||||||||||||||||||||||||||||
Doctoral Director(s:) |
Yi Ding MD, PhD | ||||||||||||||||||||||||||||||||||||||||||
Review Date: | 12/20/2022 |